This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Onychomycosis Treatment Market

Onychomycosis Treatment via Drugs to account for three-quarters of the Global Revenue Share

Onychomycosis Treatment Market by Treatment Type, Indication, Age Group, Gender, Distribution Channel & Region - Forecast 2022 - 2032

Onychomycosis Treatment Market Snapshot (2022-2032)

[335 Pages Report] The global onychomycosis treatment market is expected to display hold a value worth US$ 4.44 Billion in 2022. From 2022-2032, the onychomycosis treatment market is likely to exhibit a CAGR of 8.46% while garnering a value worth US$ 10 Billion. The growth of the market can be attributed to the growing prevalence of diabetes which results in high risks of nail fungus infection.

Data Points

Key Statistics

Expected Market Value (2022)

US$ 4.44 Billion

Anticipated Forecast Value (2032)

US$ 10 Billion

Projected Growth Rate (2022-2032)

8.46%

Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can result in chronic pain, disfigurement, and discomfort. The disease is characterized by symptoms such as whitish to yellow-brown discoloration, distortion in the shape of nails, and ragged and crumbly texture of the nails.

It is generally diagnosed through potassium, oxygen, and hydrogen examination, culture, and histopathological examinations of nail clippings and nail biopsies and are treated with laser therapy and photodynamic therapies.

The growing prevalence of chronic illnesses like human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), and onychomycosis, is one of the major factors driving the market growth during the forecast period. Also, expanding geriatric population, which is prone to such disorders due to the weakened immune system is likely to fuel the demand for the treatment during the forecast period.

Besides, the condition is highly prevalent among millennial and adults owing to the rising exposure to public swimming pools and usage of tight clothes, shoes, and socks. Other factors adding to the market growth include topical nail lacquers and ointments to maintain nail hygiene, along with the significant developments in the healthcare infrastructure as likely to augment the market size in the forthcoming time.

Additionally, increasing approvals for novel products in the industry are expected to grow the market in the assessment period. For instance, in 2022, Zydus Lifesciences received approval from the US health regulator to market antifungal Efinaconazole Topical Solution. The company received the final approval from the US FDA to market the product. Such factors are likely to widen the market growth scope during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

Global Onychomycosis Treatment Market Revenue Analysis 2017-2021 Vs Future Outlook 2022-2032

During the time span of 2017-21, the global onychomycosis treatment is anticipated to have displayed a CAGR of 8%. The expansion of the market can be attributed to increasing awareness about the threats of onychomycosis, and increasing adoption of drug therapies are some of the major factors that are likely to have contributed significantly to the development of the market.

Further, increasing cases of age-related onychomycosis is another cause that is expected to have benefitted the market. Also, increasing approval by the regulatory authorities is another vital factor to have contributed to the market growth. For instance, in July 2021, Lupin received approval to launch Tavaborole Topical Solution, 5 % in the US from the US FDA.

Tavaborole Topical Solution is a generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails owing to Trichophyton rubrum or Trichophyton mentagrophytes.

From 2022-2032, the global onychomycosis treatment market is anticipated to display a CAGR of 8.46%. The expansion of the market during the aforementioned period can be attributed to the increasing prevalence of diabetes across the globe. Diabetic patients are susceptible to toenail fungus.

Various studies and research have been performed to understand whether diabetic people experience a greater risk of onychomycosis than those without diabetes, maximum studies concluded that they do. Such factors are expected to benefit the market during the forecast period.

What Are The Factors Propelling The Global Onychomycosis Treatment Market?

Increasing Shift towards Topical Solutions to Benefit the Market

As per the analysis, the increasing preference for topical treatment solutions is expected to play a significant role in developing the market during the forecast period. As per a survey conducted on dermatologists and podiatrists in the US, 7 out of 10 doctors avoid prescribing oral terbinafine due to the risk of liver damage.

Another factor contributing to the market growth is the increasing prevalence of toenail infection caused due to onychomycosis. As per a study, about 10% of the world’s general population suffers from onychomycosis, with 35-40 million Americans being infected with nail fungus. This is anticipated to favor market growth in the coming time.

Also, the growing approval of medications by the regulatory authorities is anticipated to augment the market size significantly during the forecast period.

For instance, in 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics obtained FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails. Such factors are expected to benefit the market during the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What Are The Factors Hindering The Global Onychomycosis Treatment Market?

Lack of Awareness to Hinder the Market

The most significant factor affecting the market negatively includes the lack of awareness regarding the condition. People tend to ignore the symptoms of onychomycosis such as decolorization and thickening of the nails and separation of nails from the nail bed.

Because of this, the nail fungal infection remains undiagnosed. Further, people refrain from the treatment as they are not aware of the prevailing condition. Thus, the market is likely to suffer in the coming time. Another factor hampering the market is the associated side effects of the onychomycosis treatment drugs. Thus, the market is projected to suffer in the assessment period.

What Are The Key Trends In The Global Onychomycosis Treatment Market?

Increasing R&D Investment by Pharmaceutical Companies to Offer Remunerative Opportunities

The growing prevalence of the disease has resulted in a significant investment in R&D by pharmaceutical companies for the development of novel therapeutics. Various available topical treatment solutions fail to penetrate deep inside the nail bed and thus, do not cure the infection completely. Various players are making significant investments to offer novel drugs to meet the growing demand to cure the condition.

For instance, Hexima is conducting a phase I/IIa clinical study on HXP124, a plant defensin anti-fungal molecule for dermatophytes onychomycosis treatment. HXP124 witnessed a greater penetration rate as compared to Jublia and Kerydin. Such factors are anticipated to offer remunerative opportunities for expansion in the forthcoming time.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Segmentation Analysis

Why is the Hospital Pharmacies Segment Likely to Dominate Other Segments in the Global Onychomycosis Market?

Availability of Medicines in Hospitals to Benefit the Segmental Growth in the Forecast Period

According to the analysis, the hospital segment is anticipated to have valued at about US$ 2.2 Billion in 2021. The development of the segment can be attributed to the availability of medicines and other medical facilities there.

Also, an increasing number of privately owned clinics and the rising number of dermatologists and podiatrists are likely to develop the segment in the forecast period.

Why are Drugs Expected to Dominate the Global Onychomycosis Treatment?

Increasing R&D on Drugs to Favor the Segmental Growth

According to the analysis, the drug segment is expected to claim 75% of the global revenue during the forecast period. The domination of the segment can be attributed to the increasing focus on R&D and the convenience of this treatment type. Thus, the segment is likely to witness notable growth during the forecast period.

Regional Analysis

How is the Increasing R&D on Onychomycosis in North America Benefitting the Global Onychomycosis Treatment Market?

According to the analysis, the onychomycosis treatment market in North America is expected to dominate the global market during the forecast period. The region is projected to display a CAGR of 7% from 2022-2032.

The U.S is anticipated to make the most significant contribution to developing the industry in the assessment period. The domination of the regional market can be attributed to the increasing initiatives of players to study the disease.

For instance, in October 2020, Pfizer Inc. announced that it had commenced clinical studies on onychomycosis. The first phase involved research on determining whether the AN2690 topical solution is an effective treatment for onychomycosis of the toenail.

The second stage involved an open-label study to understand the safety and pharmacokinetics of the tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in both children and adolescents.

Another factor contributing to the market growth is the increasing cases of diabetes. As per CDC, 37.3 Million Americans, or 1 in 10 have diabetes. Such stats are expected to benefit the market in the forecast period.

How are Government Initiatives Likely to Benefit the Onychomycosis Treatment Market in Europe?

As per the study, the European onychomycosis treatment market is anticipated to display a CAGR of 5% during the forecast period. The U.K is projected to make a significant contribution to developing the regional market during the forecast period. The development of the regional market can be attributed to the growing initiatives by the government to spread awareness among citizens.

For instance, the British Association of Dermatologists offers patient information leaflets for fungal infections of the nails. Such factors are expected to benefit the onychomycosis treatment market in Europe during the forecast period.

How is the Launch of New Products in APAC Supporting the Expansion of the Onychomycosis Treatment Market?

According to the study, APAC is projected to exhibit maximum market growth during the forecast period. The rapid development of the regional market can be attributed to the presence of various developing countries making significant contributions to the advancement of healthcare services.

For instance, in 2020, Kaken Pharmaceuticals Co., Ltd announced the launch of Jublia in Hong Kong dermatophytic onychomycosis treatment. Such initiatives are expected to drive the market in APAC during the forecast period.

What Is The Contribution Of Startups In Developing The Global Onychomycosis Treatment Market?

Blueberry Therapeutics (UK), Richpoint Pharma (Canada), ToeFX (Canada), and Hallux (US), are some of the emerging names in the global onychomycosis treatment market.

Recent Development in the Startup Landscape:

  • In December 2020, Hallux, a US-based player completed a $7.1 million Series A that will allow it to conduct Phase IIa clinical trials of its drug/device combination product for onychomycosis.

Competition Analysis

Key players in the global onychomycosis treatment market include Teva Pharmaceutical Industries Ltd., Sanofi S.A., Valent Pharmaceutical, Galderma, Johnson & Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health, Inc., Pfizer Inc., Almirall, S.A., Bayer AG, Viatris Inc., GlaxoSmithKline plc, Cipla Ltd., and Dr. Reddy’s Laboratories Ltd.

Recent Developments in the Market Include:

  • In November 2021, Sanofi announced the acquisition of Kadmon Holdings. The acquisition further develops the growth and expansion of the General Medicines portfolio. Sanofi concluded its acquisition of Kadmon through the merger of a wholly owned subsidiary of Sanofi with and into Kadmon, pursuant to Section 251 of the General Corporation Law of the State of Delaware, with Kadmon continuing as the surviving corporation and becoming an indirect, wholly-owned subsidiary of Sanofi.
  • In December 2021, Pfizer Inc. and Arena Pharmaceuticals, Inc. announced that the companies have inked an agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Onychomycosis Treatment Market - Scope Of Report

Attribute

Details

Onychomycosis Treatment Market Forecast Period

2022-2032

Historical Data Available for

2017-2021

Onychomycosis Treatment Market Analysis

USD Million for value

Onychomycosis Treatment Market - Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • U.S
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • GCC
  • Turkey
  • South Africa

Onychomycosis Treatment Market - Key Segments Covered

  • Treatment Type
  • Indication
  • Age Group
  • Gender
  • Distribution Channel
  • Region

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, S.A.
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd

Report Coverage

Market Forecast, brand share analysis, competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments In The Global Onychomycosis Treatment Market

Treatment Type:

  • Drugs
    • Oral
      • Rx
      • OTC
    • Topical
      • Rx
      • OTC
  • Lasers
    • C02 Ablative Lasers
    • Nd: YAG Lasers
    • Dual-wavelength near-infrared Lasers
  • Photodynamic Therapy

Disease Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

Age Group:

  • 0-18 Years
  • 18-39 Years
  • 40-64 Years
  • 65 Years & Above

Gender:

  • Male
  • Female

Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Dermatology Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies & Online Sales

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global onychomycosis treatment market is expected to value at US$ 4.44 Billion in 2022.

The global onychomycosis treatment market is expected to secure US$ 10 Billion by 2032.

The global onychomycosis treatment market is anticipated to expand at a CAGR of 10.46% by 2032.

The onychomycosis treatment market in Europe is projected to display a CAGR of 5% during the forecast period.

The hospital segment is expected to have valued at US$ 2.2 Billion in 2021.

The onychomycosis treatment market in APAC is anticipated to display a CAGR of 5% during the forecast period.

The onychomycosis treatment market in North America is expected to display a CAGR of 7% during the forecast period.

Teva Pharmaceutical Industries Ltd., Sanofi S.A., Medimetriks Pharmaceuticals, Inc., and Galderma are some of the renowned players in the global onychomycosis treatment market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Disease Epidemiology

    4.2. Treatment Regime (Prescription Pattern)

    4.3. Key Regulation Scenario

    4.4. Pipeline Analysis

    4.5. Reimbursement Scenario

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Per Capita Healthcare Expenditure Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Social Determinants

        5.2.2. Growing Elderly Population and future Outlook

        5.2.3. New Market Development For Advanced Products Exhibit Lucrative Growth Opportunities

    5.3. Value Chain

    5.4. Market Dynamics

        5.4.1. Drivers

        5.4.2. Restraints

        5.4.3. Opportunity Analysis

6. COVID19 – Impact Analysis

    6.1. Current COVID19 Statistics and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. Current Economic Projection as compared to 2008 Economic analysis

    6.4. COVID19 and Impact Analysis

        6.4.1. Revenue By Treatment

        6.4.2. Revenue By Indication

        6.4.3. Revenue By Gender

        6.4.4. Revenue By Age Group

        6.4.5. Revenue By Distribution Channel

        6.4.6. Revenue By Country

    6.5. Recovery Scenario – Short term, Midterm and Long Term Impact

7. Global Onychomycosis Treatment Market (Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2017-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2022-2032

        8.3.1. Drugs

            8.3.1.1. Oral

                8.3.1.1.1. Rx

                8.3.1.1.2. OTC

            8.3.1.2. Topical

                8.3.1.2.1. Rx

                8.3.1.2.2. OTC

        8.3.2. Lasers

            8.3.2.1. Neodymium: yttrium-aluminum-garnet laser (Nd:YAG)

            8.3.2.2. Dual-wavelength near-infrared laser

            8.3.2.3. CO2 Ablative Laser

        8.3.3. Photodynamic Therapy

    8.4. Market Attractiveness Analysis By Treatment

9. Global Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, by Indication

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) By Indication, 2017-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        9.3.1. Distal Subungual Onychomycosis

        9.3.2. White Superficial Onychomycosis

        9.3.3. Proximal Subungual Onychomycosis

        9.3.4. Candidal Onychomycosis

        9.3.5. Total Dystrophic Onychomycosis

    9.4. Market Attractiveness Analysis By Indication

10. Global Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, by Gender

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Gender, 2017-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Gender, 2022-2032

        10.3.1. Male

        10.3.2. Female

    10.4. Market Attractiveness Analysis By Gender

11. Global Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, by Age Group

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2017-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2022-2032

        11.3.1. 0-18 Years

        11.3.2. 18-39 Years

        11.3.3. 40-64 Years

        11.3.4. 65 Years and Above

    11.4. Market Attractiveness Analysis By Gender

12. Global Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channel

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        12.3.1. Institutional Sales

            12.3.1.1. Hospitals

            12.3.1.2. Dermatology Clinics

        12.3.2. Retail Sales

            12.3.2.1. Retail Pharmacies

            12.3.2.2. Drugs Stores

        12.3.3. Mail Order Pharmacies & Online Sales

    12.4. Market Attractiveness Analysis By Gender

13. Global Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, by Region

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 - 2020

    13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2031

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. East Asia

        13.3.5. South Asia

        13.3.6. Oceania

        13.3.7. Middle East and Africa (MEA)

    13.4. Market Attractiveness Analysis By Region

14. North America Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.3.1. By Country

            14.3.1.1. U.S.

            14.3.1.2. Canada

        14.3.2. By Treatment

        14.3.3. By Indication

        14.3.4. By Gender

        14.3.5. By Age group

        14.3.6. By Distribution Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. Latin America Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        15.3.1. By Country

            15.3.1.1. Brazil

            15.3.1.2. Mexico

            15.3.1.3. Argentina

            15.3.1.4. Rest of Latin America

        15.3.2. By Treatment

        15.3.3. By Indication

        15.3.4. By Gender

        15.3.5. By Age group

        15.3.6. By Distribution Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Europe Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        16.3.1. By Country

            16.3.1.1. Germany

            16.3.1.2. Italy

            16.3.1.3. France

            16.3.1.4. U.K.

            16.3.1.5. Spain

            16.3.1.6. BENELUX

            16.3.1.7. Russia

            16.3.1.8. Rest of Europe

        16.3.2. By Treatment

        16.3.3. By Indication

        16.3.4. By Gender

        16.3.5. By Age group

        16.3.6. By Distribution Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. South Asia Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        17.3.1. By Country

            17.3.1.1. India

            17.3.1.2. Thailand

            17.3.1.3. Indonesia

            17.3.1.4. Malaysia

            17.3.1.5. Rest of South Asia

        17.3.2. By Treatment

        17.3.3. By Indication

        17.3.4. By Gender

        17.3.5. By Age group

        17.3.6. By Distribution Channel

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. East Asia Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        18.3.1. By Country

            18.3.1.1. China

            18.3.1.2. Japan

            18.3.1.3. South Korea

        18.3.2. By Treatment

        18.3.3. By Indication

        18.3.4. By Gender

        18.3.5. By Age group

        18.3.6. By Distribution Channel

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Oceania Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        19.3.1. By Country

            19.3.1.1. Australia

            19.3.1.2. New Zealand

        19.3.2. By Treatment

        19.3.3. By Indication

        19.3.4. By Gender

        19.3.5. By Age group

        19.3.6. By Distribution Channel

    19.4. Market Attractiveness Analysis

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        20.3.1. By Country

            20.3.1.1. GCC Countries

            20.3.1.2. Turkey

            20.3.1.3. South Africa

            20.3.1.4. Rest of Middle East and Africa

        20.3.2. By Treatment

        20.3.3. By Indication

        20.3.4. By Gender

        20.3.5. By Age group

        20.3.6. By Distribution Channel

    20.4. Market Attractiveness Analysis

    20.5. Key Market Participants - Intensity Mapping

    20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Onychomycosis Treatment Market Analysis 2017-2021 and Forecast 2022-2032

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Onychomycosis Treatment Market Analysis

        21.2.1. By Treatment

        21.2.2. By Indication

        21.2.3. By Gender

        21.2.4. By Age group

        21.2.5. By Distribution Channel

    21.3. Canada Onychomycosis Treatment Market Analysis

        21.3.1. By Treatment

        21.3.2. By Indication

        21.3.3. By Gender

        21.3.4. By Age group

        21.3.5. By Distribution Channel

    21.4. Brazil Onychomycosis Treatment Market Analysis

        21.4.1. By Treatment

        21.4.2. By Indication

        21.4.3. By Gender

        21.4.4. By Age group

        21.4.5. By Distribution Channel

    21.5. Mexico Onychomycosis Treatment Market Analysis

        21.5.1. By Treatment

        21.5.2. By Indication

        21.5.3. By Gender

        21.5.4. By Age group

        21.5.5. By Distribution Channel

    21.6. Argentina Onychomycosis Treatment Market Analysis

        21.6.1. By Treatment

        21.6.2. By Indication

        21.6.3. By Gender

        21.6.4. By Age group

        21.6.5. By Distribution Channel

    21.7. Germany Onychomycosis Treatment Market Analysis

        21.7.1. By Treatment

        21.7.2. By Indication

        21.7.3. By Gender

        21.7.4. By Age group

        21.7.5. By Distribution Channel

    21.8. France Onychomycosis Treatment Market Analysis

        21.8.1. By Treatment

        21.8.2. By Indication

        21.8.3. By Gender

        21.8.4. By Age group

        21.8.5. By Distribution Channel

    21.9. U.K. Onychomycosis Treatment Market Analysis

        21.9.1. By Treatment

        21.9.2. By Indication

        21.9.3. By Gender

        21.9.4. By Age group

        21.9.5. By Distribution Channel

    21.10. Spain Onychomycosis Treatment Market Analysis

        21.10.1. By Treatment

        21.10.2. By Indication

        21.10.3. By Gender

        21.10.4. By Age group

        21.10.5. By Distribution Channel

    21.11. BENELUX Onychomycosis Treatment Market Analysis

        21.11.1. By Treatment

        21.11.2. By Indication

        21.11.3. By Gender

        21.11.4. By Age group

        21.11.5. By Distribution Channel

    21.12. Russia Onychomycosis Treatment Market Analysis

        21.12.1. By Treatment

        21.12.2. By Indication

        21.12.3. By Gender

        21.12.4. By Age group

        21.12.5. By Distribution Channel

    21.13. India Onychomycosis Treatment Market Analysis

        21.13.1. By Treatment

        21.13.2. By Indication

        21.13.3. By Gender

        21.13.4. By Age group

        21.13.5. By Distribution Channel

    21.14. Thailand Onychomycosis Treatment Market Analysis

        21.14.1. By Treatment

        21.14.2. By Indication

        21.14.3. By Gender

        21.14.4. By Age group

        21.14.5. By Distribution Channel

    21.15. Indonesia Onychomycosis Treatment Market Analysis

        21.15.1. By Treatment

        21.15.2. By Indication

        21.15.3. By Gender

        21.15.4. By Age group

        21.15.5. By Distribution Channel

    21.16. Malaysia Onychomycosis Treatment Market Analysis

        21.16.1. By Treatment

        21.16.2. By Indication

        21.16.3. By Gender

        21.16.4. By Age group

        21.16.5. By Distribution Channel

    21.17. ASEAN Onychomycosis Treatment Market Analysis

        21.17.1. By Treatment

        21.17.2. By Indication

        21.17.3. By Gender

        21.17.4. By Age group

        21.17.5. By Distribution Channel

    21.18. China Onychomycosis Treatment Market Analysis

        21.18.1. By Treatment

        21.18.2. By Indication

        21.18.3. By Gender

        21.18.4. By Age group

        21.18.5. By Distribution Channel

    21.19. Japan Onychomycosis Treatment Market Analysis

        21.19.1. By Treatment

        21.19.2. By Indication

        21.19.3. By Gender

        21.19.4. By Age group

        21.19.5. By Distribution Channel

    21.20. South Korea Onychomycosis Treatment Market Analysis

        21.20.1. By Treatment

        21.20.2. By Indication

        21.20.3. By Gender

        21.20.4. By Age group

        21.20.5. By Distribution Channel

    21.21. Australia Onychomycosis Treatment Market Analysis

        21.21.1. By Treatment

        21.21.2. By Indication

        21.21.3. By Gender

        21.21.4. By Age group

        21.21.5. By Distribution Channel

    21.22. New Zealand Onychomycosis Treatment Market Analysis

        21.22.1. By Treatment

        21.22.2. By Indication

        21.22.3. By Gender

        21.22.4. By Age group

        21.22.5. By Distribution Channel

    21.23. GCC Countries Onychomycosis Treatment Market Analysis

        21.23.1. By Treatment

        21.23.2. By Indication

        21.23.3. By Gender

        21.23.4. By Age group

        21.23.5. By Distribution Channel

    21.24. Turkey Onychomycosis Treatment Market Analysis

        21.24.1. By Treatment

        21.24.2. By Indication

        21.24.3. By Gender

        21.24.4. By Age group

        21.24.5. By Distribution Channel

    21.25. South Africa Onychomycosis Treatment Market Analysis

        21.25.1. By Treatment

        21.25.2. By Indication

        21.25.3. By Gender

        21.25.4. By Age group

        21.25.5. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies

    22.2. Market Concentration

    22.3. Market Share Analysis of Top Players

    22.4. Market Presence Analysis

        22.4.1. By Regional footprint of Players

        22.4.2. Product foot print by Players

        22.4.3. Channel Foot Print by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep Dive

        23.3.1. Bausch Health

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.1.4. Sales Footprint

            23.3.1.5. Strategy Overview

                23.3.1.5.1. Marketing Strategy

                23.3.1.5.2. Product Strategy

                23.3.1.5.3. Channel Strategy

        23.3.2. Galderma S.A.

            23.3.2.1. Overview

            23.3.2.2. Product Portfolio

            23.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.2.4. Sales Footprint

            23.3.2.5. Strategy Overview

                23.3.2.5.1. Marketing Strategy

                23.3.2.5.2. Product Strategy

                23.3.2.5.3. Channel Strategy

        23.3.3. Novartis AG

            23.3.3.1. Overview

            23.3.3.2. Product Portfolio

            23.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.3.4. Sales Footprint

            23.3.3.5. Strategy Overview

                23.3.3.5.1. Marketing Strategy

                23.3.3.5.2. Product Strategy

                23.3.3.5.3. Channel Strategy

        23.3.4. Pfizer, Inc.

            23.3.4.1. Overview

            23.3.4.2. Product Portfolio

            23.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.4.4. Sales Footprint

            23.3.4.5. Strategy Overview

                23.3.4.5.1. Marketing Strategy

                23.3.4.5.2. Product Strategy

                23.3.4.5.3. Channel Strategy

        23.3.5. Moberg Pharma AB

            23.3.5.1. Overview

            23.3.5.2. Product Portfolio

            23.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.5.4. Sales Footprint

            23.3.5.5. Strategy Overview

                23.3.5.5.1. Marketing Strategy

                23.3.5.5.2. Product Strategy

                23.3.5.5.3. Channel Strategy

        23.3.6. Bayer AG

            23.3.6.1. Overview

            23.3.6.2. Product Portfolio

            23.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.6.4. Sales Footprint

            23.3.6.5. Strategy Overview

                23.3.6.5.1. Marketing Strategy

                23.3.6.5.2. Product Strategy

                23.3.6.5.3. Channel Strategy

        23.3.7. Dr. Reddy’s Laboratories Ltd.

            23.3.7.1. Overview

            23.3.7.2. Product Portfolio

            23.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.7.4. Sales Footprint

            23.3.7.5. Strategy Overview

                23.3.7.5.1. Marketing Strategy

                23.3.7.5.2. Product Strategy

                23.3.7.5.3. Channel Strategy

        23.3.8. Cipla Ltd.

            23.3.8.1. Overview

            23.3.8.2. Product Portfolio

            23.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.8.4. Sales Footprint

            23.3.8.5. Strategy Overview

                23.3.8.5.1. Marketing Strategy

                23.3.8.5.2. Product Strategy

                23.3.8.5.3. Channel Strategy

        23.3.9. Medimetriks Pharmaceuticals, Inc.

            23.3.9.1. Overview

            23.3.9.2. Product Portfolio

            23.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.9.4. Sales Footprint

            23.3.9.5. Strategy Overview

                23.3.9.5.1. Marketing Strategy

                23.3.9.5.2. Product Strategy

                23.3.9.5.3. Channel Strategy

        23.3.10. Sanofi S.A.

            23.3.10.1. Overview

            23.3.10.2. Product Portfolio

            23.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.10.4. Sales Footprint

            23.3.10.5. Strategy Overview

                23.3.10.5.1. Marketing Strategy

                23.3.10.5.2. Product Strategy

                23.3.10.5.3. Channel Strategy

        23.3.11. GlaxoSmithKline Plc.

            23.3.11.1. Overview

            23.3.11.2. Product Portfolio

            23.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.11.4. Sales Footprint

            23.3.11.5. Strategy Overview

                23.3.11.5.1. Marketing Strategy

                23.3.11.5.2. Product Strategy

                23.3.11.5.3. Channel Strategy

        23.3.12. Teva Pharmaceutical industries Ltd.

            23.3.12.1. Overview

            23.3.12.2. Product Portfolio

            23.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.12.4. Sales Footprint

            23.3.12.5. Strategy Overview

                23.3.12.5.1. Marketing Strategy

                23.3.12.5.2. Product Strategy

                23.3.12.5.3. Channel Strategy

        23.3.13. Cardinal Health Inc.

            23.3.13.1. Overview

            23.3.13.2. Product Portfolio

            23.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.13.4. Sales Footprint

            23.3.13.5. Strategy Overview

                23.3.13.5.1. Marketing Strategy

                23.3.13.5.2. Product Strategy

                23.3.13.5.3. Channel Strategy

        23.3.14. Viatris Inc.

            23.3.14.1. Overview

            23.3.14.2. Product Portfolio

            23.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.14.4. Sales Footprint

            23.3.14.5. Strategy Overview

                23.3.14.5.1. Marketing Strategy

                23.3.14.5.2. Product Strategy

                23.3.14.5.3. Channel Strategy

        23.3.15. Almirall, S.A

            23.3.15.1. Overview

            23.3.15.2. Product Portfolio

            23.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.15.4. Sales Footprint

            23.3.15.5. Strategy Overview

                23.3.15.5.1. Marketing Strategy

                23.3.15.5.2. Product Strategy

                23.3.15.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 02: Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 03: Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 04: Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Age Group

Table 05: Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 06: Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Region

Table 07: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 08: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 09: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 10: North America Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 11: North America Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 12: North America Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 13: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 14: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 15: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 16: Latin America Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 17: Latin America Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 18: Latin America Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 19: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 20: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 21: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 22: Europe Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 23: Europe Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 24: Europe Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 25: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 26: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 27: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 28: South Asia Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 29: South Asia Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 30: South Asia Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 31: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 32: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 33: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 34: East Asia Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 35: East Asia Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 36: East Asia Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 37: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 38: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 39: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 40: Oceania Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 41: Oceania Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 42: Oceania Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Table 43: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 44: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Table 45: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Table 46: MEA Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Gender

Table 47: MEA Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Age Group

Table 48: MEA Onychomycosis Treatment Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channels

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 02: Global Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 03: Global Onychomycosis Treatment Market Absolute $ Opportunity Analysis, 2022-2032

Figure 04: Global Onychomycosis Treatment Market Analysis by Treatment Type –2022 & 2032

Figure 05: Global Onychomycosis Treatment Market Y-o-Y Growth Projections by Treatment Type, 2022-2032

Figure 06: Global Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type

Figure 07: Global Onychomycosis Treatment Market Analysis by Indication –2022 & 2032

Figure 08: Global Onychomycosis Treatment Market Y-o-Y Growth Projections by Indication, 2022-2032

Figure 09: Global Onychomycosis Treatment Market Attractiveness Analysis 2022-2032, by Indication

Figure 10: Global Onychomycosis Treatment Market Analysis by Gender –2022 & 2032

Figure 11: Global Onychomycosis Treatment Market Y-o-Y Growth Projections by Gender, 2022-2032

Figure 12: Global Onychomycosis Treatment Market Attractiveness Analysis 2022-2032, By Gender

Figure 13: Global Onychomycosis Treatment Market Analysis by Age Group –2022 & 2032

Figure 14: Global Onychomycosis Treatment Market Y-o-Y Growth Projections by Age Group, 2022-2032

Figure 15: Global Onychomycosis Treatment Market Attractiveness Analysis 2022-2032, by Age Group

Figure 16: Global Onychomycosis Treatment Market Analysis by Distribution Channel –2022 & 2032

Figure 17: Global Onychomycosis Treatment Market Y-o-Y Growth Projections by Distribution Channel, 2022-2032

Figure 18: Global Onychomycosis Treatment Market Attractiveness Analysis 2022-2032, by Distribution Channel

Figure 19: Global Onychomycosis Treatment Market Analysis by Region–2022 & 2032

Figure 20: Global Onychomycosis Treatment Market Y-o-Y Growth Projections by Region, 2022-2032

Figure 21: Global Onychomycosis Treatment Market Attractiveness Analysis 2022-2032, By Region

Figure 22: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 23: North America Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 24: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Country

Figure 25: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type

Figure 26: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Figure 27: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Gender

Figure 28: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, Age Group

Figure 29: North America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Distribution Channel

Figure 30: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 31: Latin America Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 32: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Country

Figure 33: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Treatment Type

Figure 34: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Indication

Figure 35: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Gender

Figure 36: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Age Group

Figure 37: Latin America Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Distribution Channel

Figure 38: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 39: Europe Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 40: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Country

Figure 41: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type

Figure 42: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Indication

Figure 43: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,By Gender

Figure 44: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Age Group

Figure 45: Europe Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channel

Figure 46: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 47: South Asia Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 48: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,byCountry

Figure 49: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,byTreatment Type

Figure 50: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Indication

Figure 51: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,byGender

Figure 52: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Age Group

Figure 53: South Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,byDistribution Channel

Figure 54: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 55: East Asia Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 56: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Country

Figure 57: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,byTreatment Type

Figure 58: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Indication

Figure 59: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Gender

Figure 60: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Age Group

Figure 61: East Asia Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Distribution Channel

Figure 62: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 63: Oceania Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 64: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Country

Figure 65: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type

Figure 66: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, Indication

Figure 67: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Gender

Figure 68: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,Age Group

Figure 69: Oceania Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channel

Figure 70: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis, 2017-2021

Figure 71: MEA Onychomycosis Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 72: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Country

Figure 73: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Treatment Type

Figure 74: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, Indication

Figure 75: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032,by Gender

Figure 76: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, Age Group

Figure 77: MEA Onychomycosis Treatment Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channel

Figure 78: U.S. Market Value Proportion Analysis

Figure 79: U.S. Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 80: U.S. Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 81: U.S. Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 82: U.S. Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 83: U.S. Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 84: Global Vs. U.S. Growth Comparison

Figure 85: Canada Market Value Proportion Analysis

Figure 86: Canada Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 87: Canada Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 88: Canada Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 89: Canada Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 90: Canada Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 91: Global Vs. Canada Growth Comparison

Figure 92: Brazil Market Value Proportion Analysis

Figure 93: Brazil Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 94: Brazil Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 95: Brazil Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 96: Brazil Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 97: Brazil Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 98: Global Vs. Brazil Growth Comparison

Figure 99: Mexico Market Value Proportion Analysis

Figure 100: Mexico Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 101: Mexico Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 102: Mexico Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 103: Mexico Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 104: Mexico Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 105: Global Vs. Mexico Growth Comparison

Figure 106: Rest of LA Market Value Proportion Analysis

Figure 107: Rest of LA Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 108: Rest of LA Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 109: Rest of LA Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 110: Rest of LA Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 111: Rest of LA Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 112: Global Vs. Rest of LA Growth Comparison

Figure 113: Germany Market Value Proportion Analysis

Figure 114: Germany Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 115: Germany Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 116: Germany Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 117: Germany Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 118: Germany Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 119: Global Vs. Germany Growth Comparison

Figure 120: Italy Market Value Proportion Analysis

Figure 121: Italy Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 122: Italy Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 123: Italy Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 124: Italy Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 125: Italy Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 126: Global Vs. Italy Growth Comparison

Figure 127: France Market Value Proportion Analysis

Figure 128: France Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 129: France Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 130: France Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 131: France Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 132: France Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 133: Global Vs. France Growth Comparison

Figure 134: U.K. Market Value Proportion Analysis

Figure 135: U.K. Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 136: U.K. Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 137: U.K. Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 138: U.K. Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 139: Global Vs. U.K. Growth Comparison

Figure 140: U.K. Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 141: Spain Market Value Proportion Analysis

Figure 142: Spain Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 143: Spain Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 144: Spain Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 145: Spain Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 146: Spain Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 147: Global Vs. Spain Growth Comparison

Figure 148: BENELUX Market Value Proportion Analysis

Figure 149: BENELUX Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 150: BENELUX Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 151: BENELUX Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 152: BENELUX Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 153: BENELUX Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 154: Global Vs. BENELUX Growth Comparison

Figure 155: Russia Market Value Proportion Analysis

Figure 156: Russia Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 157: Russia Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 158: Russia Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 159: Russia Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 160: Russia Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 161: Global Vs. Russia Growth Comparison

Figure 162: Rest of Europe Market Value Proportion Analysis

Figure 163: Rest of Europe Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 164: Rest of Europe Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 165: Rest of Europe Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 166: Rest of Europe Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 167: Rest of Europe Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 168: Global Vs. Rest of Europe Growth Comparison

Figure 169: India Market Value Proportion Analysis

Figure 170: India Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 171: India Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 172: India Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 173: India Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 174: India Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 175: Global Vs. India Growth Comparison

Figure 176: Thailand Market Value Proportion Analysis

Figure 177: Thailand Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 178: Thailand Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 179: Thailand Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 180: Thailand Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 181: Thailand Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 182: Global Vs. Thailand Growth Comparison

Figure 183: Indonesia Market Value Proportion Analysis

Figure 184: Indonesia Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 185: Indonesia Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 186: Indonesia Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 187: Indonesia Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 188: Indonesia Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 189: Global Vs. Indonesia Growth Comparison

Figure 190: Malaysia Market Value Proportion Analysis

Figure 191: Malaysia Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 192: Malaysia Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 193: Malaysia Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 194: Malaysia Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 195: Malaysia Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 196: Global Vs. Malaysia Growth Comparison

Figure 197: Rest of SA Market Value Proportion Analysis

Figure 198: Rest of SA Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 199: Rest of SA Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 200: Rest of SA Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 201: Rest of SA Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 202: Rest of SA Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 203: Global Vs. Rest of SA Growth Comparison

Figure 204: China Market Value Proportion Analysis

Figure 205: China Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 206: China Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 207: China Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 208: China Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 209: China Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 210: Global Vs. China Growth Comparison

Figure 211: Japan Market Value Proportion Analysis

Figure 212: Japan Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 213: Japan Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 214: Japan Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 215: Japan Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 216: Japan Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 217: Global Vs. China Growth Comparison

Figure 218: South Korea Market Value Proportion Analysis

Figure 219: South Korea Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 220: South Korea Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 221: South Korea Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 222: South Korea Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 223: Global Vs. South Korea Growth Comparison

Figure 224: South Korea Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 225: Australia Market Value Proportion Analysis

Figure 226: Australia Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 227: Australia Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 228: Australia Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 229: Australia Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 230: Global Vs. Australia Growth Comparison

Figure 231: Australia Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 232: New Zealand Market Value Proportion Analysis

Figure 233: New Zealand Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 234: New Zealand Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 235: New Zealand Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 236: New Zealand Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 237: New Zealand Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 238: Global Vs. New Zealand Growth Comparison

Figure 239: GCC Market Value Proportion Analysis

Figure 240: GCC Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 241: GCC Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 242: GCC Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 243: GCC Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 244: GCC Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 245: Global Vs. GCC Growth Comparison

Figure 246: Turkey Market Value Proportion Analysis

Figure 247: Turkey Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 248: Turkey Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 249: Turkey Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 250: Turkey Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 251: Turkey Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 252: Global Vs. Turkey Growth Comparison

Figure 253: Northern Africa Market Value Proportion Analysis

Figure 254: Northern Africa Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 255: Northern Africa Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 256: Northern Africa Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 257: Northern Africa Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 258: Global Vs. Northern Africa Growth Comparison

Figure 259: Northern Africa Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 260: South Africa Market Value Proportion Analysis

Figure 261: South Africa Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 262: South Africa Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 263: South Africa Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 264: South Africa Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 265: Global Vs. South Africa Growth Comparison

Figure 266: South Africa Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Figure 267: Rest of MEA Market Value Proportion Analysis

Figure 268: Rest of MEA Onychomycosis Treatment Market Share Analysis (%) By Treatment Type, 2020

Figure 269: Rest of MEA Onychomycosis Treatment Market Share Analysis (%) By Indication, 2020

Figure 270: Rest of MEA Onychomycosis Treatment Market Share Analysis (%) By Age Group, 2020

Figure 271: Rest of MEA Onychomycosis Treatment Market Share Analysis (%) By Gender, 2020

Figure 272: Global Vs. Rest of MEA Growth Comparison

Figure 273: Rest of MEA Onychomycosis Treatment Market Share Analysis (%) By Distribution Channel, 2020

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Folliculotropic Mycosis Fungoides Treatment Market

Published : February 2021

Healthcare

Fungal Testing Kits Market

Published : September 2020

Healthcare

Fungal Keratitis Treatment Market

Published : June 2018

Healthcare

Zygomycosis Treatments Market

Published : June 2018

Google translate

Onychomycosis Treatment Market